HSD17B13基因rs72613567:TA多态性与肝细胞癌确诊后生存获益相关
基于英国生物银行(UKB)中确诊肝细胞癌(HCC)的439例参与者,随访至死亡或登记截止,平均随访1.9年,期间321例死亡。多因素Cox回归显示rs72613567:TA(HSD17B13)是唯一与全因死亡风险显著相关的易感变异(aHR 0.74;95%CI 0.61-0.90;p=0.003)。作者认为该多态性不仅降低HCC发生风险,在HCC确诊后也与生存获益相关。
要点
- 在439例HCC患者中,rs72613567:TA(HSD17B13)与全因死亡风险降低相关(aHR 0.74;95%CI 0.61-0.90;p=0.003)。
- Baveno 3-4期与死亡风险升高相关(aHR 1.65;95%CI 1.05-2.59;p=0.03)。
- 以治愈为目的的HCC治疗与死亡风险降低相关(aHR 0.25;95%CI 0.17-0.37;p<0.001)。
核心结论
- HSD17B13的rs72613567:TA多态性不仅与HCC发生风险降低相关,在HCC确诊后也与生存获益相关。
- 作者认为,治疗性抑制HSD17B13可能提高HCC患者的生存率。
研究设计与样本
- 研究纳入英国生物银行(UKB)中入组后确诊HCC的参与者,从HCC诊断日期随访至死亡或登记截止日期。
- 最终样本439例,采用Cox回归分析5个HCC易感位点与HCC死亡风险的关联,并校正年龄、性别、种族、病因、基础肝病严重程度及是否接受治愈性HCC治疗。
主要发现
- 最终样本439例,74%患有非酒精性脂肪性肝病或酒精相关性肝病。
- 平均每人随访1.9年,期间共321例死亡。
- Kaplan-Meier生存估计:1年53.2%、3年31.2%、5年22.6%。
- 多因素分析中,rs72613567:TA(HSD17B13)是唯一与全因死亡风险显著相关的遗传易感变异(aHR 0.74;95%CI 0.61-0.90;p=0.003)。
- 其他相关因素:Baveno 3-4期(aHR 1.65;95%CI 1.05-2.59;p=0.03)和以治愈为目的的HCC治疗(aHR 0.25;95%CI 0.17-0.37;p<0.001)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The influence of genetic factors on survival following a diagnosis of hepatocellular carcinoma (HCC) remains unclear. AIM: To assess whether genetic polymorphisms influencing the susceptibility to develop HCC are also associated with HCC prognosis. METHODS: We included United Kingdom Biobank (UKB) participants diagnosed with HCC after study enrolment. The primary outcome was all-cause mortality. Patients were followed from the date of HCC diagnosis to death or the registry completion date. Five HCC susceptibility loci were investigated: rs738409 (PNPLA3), rs58542926 (TM6SF2); rs72613567 (HSD17B13); rs2242652 (TERT) and rs708113 (WNT3A). The associations between these genetic variants and HCC mortality risk were assessed using Cox regression, adjusted for age, sex, ethnicity, aetiology, severity of the underlying liver disease and receipt of curative HCC treatment. RESULTS: The final sample included 439 patients; 74% had either non-alcoholic fatty liver disease or alcohol-related liver disease. There were 321 deaths during a mean follow-up of 1.9 years per participant. Kaplan-Meier survival estimates at 1, 3 and 5 years were 53.2%, 31.2% and 22.6% respectively. In multivariate analysis, rs72613567:TA (HSD17B13) was the only genetic susceptibility variant significantly associated with all-cause mortality risk (aHR: 0.74; 95% CI: 0.61-0.90; p = 0.003). Other associated factors were Baveno stage 3-4 (aHR: 1.65; 95% CI: 1.05-2.59; p = 0.03) and HCC treatment with curative intent (aHR: 0.25; 95% CI: 0.17-0.37; p < 0.001). CONCLUSIONS: The rs72613567:TA polymorphism in HSD17B13 is not only associated with a reduction in the risk of developing HCC but with a survival benefit in HCC once established. Therapeutic inhibition of HSD17B13 may augment survival in individuals with HCC.
引用
- Innes H, Morgan MY, Hampe J, et al. The rs72613567:TA polymorphism in HSD17B13 is associated with survival benefit after development of hepatocellular carcinoma. Aliment Pharmacol Ther. 2023. PMID: 37470344. doi:10.1111/apt.17638
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。